anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: The primary aim of this scoping review was to explore and categorize the medication-related self-care behaviours exhibited by patients with non-valvular atrial fibrillation (NVAF) who are on oral anticoagulant (OAC) therapy.
METHODS AND RESULTS: A scoping review was performed, and the systematic search of the literature yielded an initial 887 records. After deduplication and screening, 61 studies were included in the analysis, ranging from 2003 to 2023. The studies represented a wide geographical distribution and diverse methodologies. The results identified 16 self-care behaviours: a higher focus of the included literature on self-care monitoring (60.65% of studies), followed by self-care management and self-care maintenance (each 16.39%). These behaviours ranged from regular blood testing to consulting healthcare providers and lifestyle changes. The results also highlighted the relationship between treatment satisfaction, self-efficacy, and adherence. Several studies emphasized the critical role of healthcare providers in influencing medication adherence. Furthermore, patient knowledge, quality of life, and psychological factors were identified as key elements affecting self-care behaviours.
CONCLUSION: The review provides a comprehensive landscape of medication-related self-care behaviours among NVAF patients on OAC therapy. It underscores the predominance of self-care monitoring behaviours and the critical roles of healthcare providers, psychological factors, and patient knowledge in influencing these behaviours. The findings also highlight the necessity for an integrated, patient-centred approach to improving self-care and self-management in OAC treatment. Future research should focus on addressing the identified gaps, including the relative lack of studies on lifestyle modification, emotional well-being, and technology-assisted interventions.
REGISTRATION: This review is part of a broader project and is documented at ClinicalTrials.gov: NCT05820854.
Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
OBJECTIVES: To evaluate the association between low back pain (LBP) and painful temporomandibular disorders (TMDs).
METHODS: Systematic review of observational studies. Searches were conducted using OVID MEDLINE, CINHAL, Web of Science and PUBMED databases up to 21 October 2022. Qualitative and quantitative analyses were performed. Risk of bias (RoB) was assessed using the Quality in Prognosis Studies tool (QUIPS).
RESULTS: Eight studies were included in the present review with meta-analysis. The first onset of TMDs was more likely in patients with previous chronic LBP (hazard ratio (HR) 1.53 [95% confidence interval (CI): 1.28; 1.83, p < .00001]). In addition, patients with chronic LBP had 3.25 times the odds (OR) [95% CI: 1.94; 5.43, p < .00001] of having chronic TMDs than those who did not have chronic LBP. In addition, the higher the exposure to chronic LBP, the higher the risk of developing a first onset of TMDs.
CONCLUSIONS: Chronic LBP can be considered a risk/contributing factor for painful TMDs. Although there is a high certainty in the evidence linking chronic LBP with the risk of a first onset of TMDs, there are insufficient studies to draw definitive conclusions. Furthermore, while an association between chronic LBP and chronic TMDs and a dose-effect was observed between these two conditions, a limited number of studies and evidence exist to support these findings. Future studies are needed to increase the body of evidence.
Avoid accidental transfer of tazarotene cream into eyes, mouth, or other mucous membranes. If contact with mucous membranes occurs, rinse thoroughly with water [see Warnings and Precautions (5.2)].

Wash hands thoroughly after application.

Emollients or moisturizers can be applied either before or after applying tazarotene cream. However, ensure that the first cream or lotion has absorbed into the skin and has dried completely before subsequent cream or lotion application. Use facial moisturizers as frequently as desired [see Warnings and Precautions (5.2)].

Tazarotene cream is for topical use only. Tazarotene cream is not for ophthalmic, oral, or intravaginal use.

Use effective sunscreens and wear protective clothing while using tazarotene cream [see Warnings and Precautions (5.3)].
Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
PURPOSE:To obtain the subject herb medicinal hard capsule, having a high extract content and a short elution time of the contents and excellent in elution properties. CONSTITUTION:The objective herb medicinal hard capsule is obtained by adding magnesium stearate in an amount of 0.01-5wt.%, preferably 0.5-3.0wt.% based on dry extract powder to particles prepared by compacting dry extract powder of a herb medicine. This herb medicinal hard capsule is good in eluting properties of quickly eluting the contents. Furthermore, the herb medicine is not especially limited; however, e.g. ORENGEDOKUTO (a decoction containing Coptidis Rhizoma, Phellondedri Cortex, Scutellariae Radix, etc.), NINJINTO (a decoction containing Ginseng Radix, Glycyrrhizae Radix, etc.), SHOSAIKOTO (a decoction containing Bupleuri Radix, Pinelliae Tuber, Scutellariae Radix, etc.), MAOBUSHISAISHINTO (a decoction containing Ephedrae Herba, Asiasari Radix, Aconiti Sinensis Tuber, etc.), ANCHUSAN (powder containing Cinnamomi Cortex, Corydalis Tuber, Ostreae Testa, Foeniculi Fructus, etc.), KEISHIBURYOGAN (a pill containing Cinnamomi Cortex, Hoelen, Moutan Cortex, etc.), BYAKKOKANINJINTO (a decoction containing Anemarrhenae Rhizoma, Gypsum, Glycyrrhizae Radix, Ginseng Radix, etc.), SHAKUYAKUKANZOTO (a decoction containing Paeoniae Radix, Glycyrrhizae Radix, etc.) and SANOSHASHINTO (a decoction containing Rhei Rhizoma, Scutellariae Radix, Coptidis Rhizoma, etc.) are preferred.
FIELD: medicine, particularly, stomatology. SUBSTANCE: essence of new method resides in that perphenazine is to be used as antiemetic preparation two or three days before cast is taken and dental prosthesis is properly fitted. Perphenazine is to be taken in dosage of up to 8 mg three times a day. New method further prescribes placing 1 tablet of phalimint under patient's tongue 30 min before denture fitting is started and then taking perphenazime in dose of 6 mg three times a day and 1 tablet of phalimint under tongue three times a day during 4 to 6 days. EFFECT: better functional results. 2 tbl
INTRODUCTION: Pediatric nephrology prenatal consultations for congenital anomalies of the kidney and urinary tract (CAKUT) and criteria for kidney replacement therapy initiation in neonatal end-stage kidney disease (ESKD) are not well described. We evaluated pediatric nephrology approaches to prenatal CAKUT counseling and neonatal dialysis initiation.
METHODS: A 35-question Qualtrics survey was distributed via the North American Pediatric Renal Trials and Collaborative Studies email list between January and March 2021. Thirty-nine pediatric nephrology centers completed the survey.
RESULTS: All but one responding center (n = 38) provide prenatal CAKUT consultations and neonatal dialysis, with wide variability in reported multispecialty involvement. Nearly half (47%) of centers utilize written/unwritten criteria for offering neonatal dialysis. The most common contraindications to neonatal dialysis were parental refusal (61%), contraindication to access placement by surgeons (55%), and birth weight (BW) contraindication (55%, with < 1,500 g being the most common BW contraindication). Overall, 79% of centers reported caring for < 5 neonates with ESKD in the past year, 61% use hemodialysis therapies prior to peritoneal dialysis in neonates requiring dialysis, and 100% transition to peritoneal dialysis by hospital discharge.
CONCLUSION: Many pediatric nephrology programs provide prenatal CAKUT consultations and neonatal dialysis, but with variability in practice approach. Further multicenter research regarding prenatal consultations and neonatal dialysis outcomes is necessary to further improve care delivery to this population.
The use of sulfated oligosaccharides, particularly mono- and disaccharides, and their salts to enhance healing of wounds is described. Preferred saccharides are those having three or more sulfate groups, with persulfation being most preferred. Preferred salts are the soluble salts most preferably the alkali metal salts, particularly potassium and sodium salts. Sucrose octosulfate is the most preferred material. The saccharides may be used in any form, including liquids, gels or time release polymers. In preferred practice the saccharide is used in combination with collagen. Wounds, in particular those ocurring in the skin and bone tissues, may be treated with the compositions. Wound healing is promoted even in wounds, such as decubitis ulcers, which are commonly resistent to the natural healing process.
Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
A 2-year-old castrated Russian Blue cat presented with inappetence, depression, and labored respirations. Radiography findings suggested left lung atelectasis; however, the ultrasonography findings did not indicate lung atelectasis. The left pulmonary artery (PA) was abnormally small on echocardiography; further, there were no other cardiac anomalies. Computed tomography revealed an abnormally small left PA and left lung. Furthermore, bronchiectasis and tree-in-bud patterns were observed in the lung lobes. Based on these findings, the cat was diagnosed with isolated left PA hypoplasia, presumed left lung hypoplasia, and feline chronic bronchial disease. Early diagnosis of this disease is important because it can cause serious complications, including recurrent respiratory infection, bronchiectasis, massive hemoptysis, and pulmonary hypertension.
Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
A cream for the skin or for use when shaving is prepared by dissolving in water a soap containing an excess of potassium or sodium hydroxide, and mixing in a magnesium salt, e.g. magnesium sulphate, so as to form a suspension of magnesium hydroxide in the cream.ALSO:A cream for medicinal application to the skin is prepared by dissolving in water a soap manufactured from palmitic, stearic, and/or oleic acid and an excess of potassium or sodium hydroxide, adding a magnesium salt, and intermingling the mass to enable the free alkali in the soap to precipitate magnesium hydroxide in a creamy or milky condition so that it remains in suspension in the cream.  Suitable proportions are 24 lbs. of soap, 150 to 175 lbs. of water, and 4 to 6 lbs. of magnesium sulphate.
The safety and efficacy of ULTRAVIST Injection have been established in the pediatric population over 2 years of age. Use of ULTRAVIST Injection in these age groups is supported by evidence from adequate and well controlled studies of ULTRAVIST Injection in adults and additional safety data obtained in literature and other reports in a total of 274 pediatric patients. Of these, there were 131 children (2–12 years), 57 adolescents, and 86 children of unreported or other ages. There were 148 females, 94 males and 32 in whom gender was not reported. The racial distribution was: Caucasian 93 (33.9%), Black 1 (0.4%), Asian 6 (2.2%), and unknown 174 (63.5%). These patients were evaluated in intra-arterial coronary angiographic (n=60), intravenous contrast computerized tomography (CT) (n=87), excretory urography (n=99) and 28 other procedures. 

In these pediatric patients, a concentration of 300 mg Iodine per mL was employed for intravenous contrast CT or excretory urography. A concentration of 370 mg Iodine per mL was employed for intra-arterial and intracardiac administration in the radiographic evaluation of the heart cavities and major arteries. Most pediatric patients received initial volumes of 1–2 mL/kg. 

Optimal doses of ULTRAVIST Injection have not been established because different injection volumes, concentrations and injection rates were not studied. The relationship of the volume of injection with respect to the size of the target vascular bed has not been established. The potential need for dose adjustment on the basis of immature renal function has not been established. In the pediatric population, the pharmacokinetic parameters have not been established.

Pediatric patients at higher risk of experiencing an adverse reaction during and after administration of any contrast agent include those with asthma, a sensitivity to medication and/or allergens, cyanotic and acyanotic heart disease, congestive heart failure, or a serum creatinine greater than 1.5 mg/dL. 

Thyroid function tests indicative of thyroid dysfunction, characterized by hypothyroidism or transient thyroid suppression have been reported following iodinated contrast media administration in pediatric patients, including term and preterm neonates; some patients were treated for hypothyroidism. After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0 to 3 years of age based on underlying risk factors, especially in term and preterm neonates [see Warnings and Precautions (5.6) and Adverse Reactions (6.2)].

The injection rates in small vascular beds, and the relationship of the dose by volume or concentration in small pediatric patients have not been established. Exercise caution in selecting the dose.

Safety and effectiveness in pediatric patients below the age of two have not been established.
FIELD: medicine. SUBSTANCE: invention relates to method of conservation of raw activity for soluble thromboplastin preparing. Method involves addition of sucrose in the amount that is necessary to obtain 2-% final solution to the raw prepared from cadaverous brain gray matter homogenate. Then sodium metabisulfite is dissolved to obtain 0.005 M solution and buffer containing citric acid/sodium citrate (pH 6.0-6.5) is added in the amount 1 ml/100 ml of supernatant. Invention provides preparing soluble thromboplastin in the frozen state up to minus 30 ± 2 C and prevents its destruction during lyophilization. EFFECT: increased storage period up to 4 weeks, increased stability. 1 cl, 3 tbl, 1 ex
PURPOSE:To obtain a rapid acting therapeutic agent for atopic dermatitis, containing an interferon as an active ingredient and capable of sustaining the pharmacodynamic effects. CONSTITUTION:The therapeutic agent for atopic dermatitis is obtained by including an interferon, especially preferably a natural type interferon beta produced by a human diploid fibroblast as an active ingredient. A stabilizer, etc., as necessary, are blended therewith and the resultant blend can be prepared into a form such as a parenteral injection, a capsule, a pernasal agent, a suppository, an oral agent or an ointment. The dose is 30-8000000 units/day, preferably 50-7000000 units/day. This therapeutic agent is capable of remarkably reducing the number of eosinophiles in blood and improving the atopic dermatitic symptoms. The ointment therapy using corticosteroid requiring the administration for a long period is the nucleus of the pharmacotherapy for the atopic dermatitis. Thereby, both local side effects caused in sites of external application and systemic side effects due to the absorption and entry of the corticosteroid in blood and an influence on other organs are recognized in the corticosteroid.
Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
Recently developed and passed extensive pre-clinical testing collagen-phosphorylcholine(RHCIII-MPC) corneal substitute will be implanted in patient's corneas with corneal scar (leukoma) developed after infection, trauma or keratoconus using anterior lamellar keratoplasty technique, i.e. once patient's diseased anterior part of cornea is removed, either manually or with assistance of femtosecond laser, it will be substituted with proposed transparent implant. Control patients with same condition will be grafted with human donor cornea using the same surgical technique.

The investigators will test the safety and the effectiveness of developed biosynthetic corneas. Overall 20 patients are planned to recruit. They will be randomized in two groups - 10 patients will undergo RHCIII-MPC cornea implantation, another 10 will be impanted with human donor cornea. The patients will be follow-uped for 12 months.
BACKGROUND: Thoracoscopic repair of esophageal atresia (EA) with tracheoesophageal fistula (TEF) is becoming an increasingly widespread technique; there is still controversy about its indication in certain patients. Our objective is to analyze if potential risk factors such as major congenital heart disease (CHD) or low birth weight (LBW) are a limitation to this approach.
METHODS: Retrospective study (2017-2021) of patients with EA and distal TEF who underwent thoracoscopic repair were included. Patients with LBW less than 2,000 g or major CHD were compared with the rest.
RESULTS: Twenty-five patients underwent thoracoscopic surgery. Nine patients (36%) had major CHD. Five of them (20%) were LBW less than 2,000 g, and only 8% (2/25) presented both risk factors. There were no differences in terms of operative time, conversion rate, tolerance evaluated with gasometric parameters (pO2, pCO2, pH) or complications (anastomotic leak and stricture, both early or during follow-up) in patients with major CHD and LBW (1,473 ± 319 vs. 2,664 ± 402 g). One conversion to thoracotomy was performed in a neonate weighing 1,050 g due to anesthetic intolerance. There was no recurrence of TEF. One patient died at the age of 9 months, due to major uncorrectable heart disease.
CONCLUSION: Thoracoscopic repair of EA/TEF is feasible technique in patients with CHD or LBW, with similar results to other patients. The complexity of this technique warrants individualizing the indication in each case.
LEVEL OF EVIDENCE: IV.
The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
Bulimia nervosa (BN) is a common eating disorder that is characterized by periods of bingeing and purging. People with the dysregulated subtype of BN experience behavioral impulsivity; disruption of cognitive, affective, behavioral, and neurophysiological processes (dysregulation); interpersonal dysfunction; and poor treatment response. To date, no therapies have been tested for this specific population, and it is unknown whether therapy that directly focuses on treating BN symptoms or one that addresses both eating and personality disorder symptoms is more effective. Cognitive behavioral therapy (CBT), which concentrates on modifying patients' behaviors and ways of thinking, has been effective in treating BN. This study will compare the effectiveness of two types of CBT, focused and broad, in treating adult women with the dysregulated subtype of BN.

Participants in this single-blind study will be randomly assigned to receive 20 sessions of either broad (enhanced) or focused CBT. Participants will meet with a therapist once or twice weekly until 20 sessions have occurred. Broad CBT will address symptoms of BN, as well as those of the personality disorder. Focused CBT will concentrate only on BN symptoms. Before treatment begins, participants will complete a set of questionnaires pertaining to their experiences with BN, depression, anxiety, and interpersonal relationships. The questionnaires will be used throughout the study to assess participants' progress. Participants will also attend a clinical interview lasting approximately 3.5 hours. Questions will concern BN, other eating disorder symptoms, depression, anxiety, and interpersonal relationships. Blood samples and vital signs will also be taken at the time of the clinical interview and as needed later in the treatment process.
Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck \& Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
Famotidine is incompletely absorbed. The bioavailability of oral doses is 40 to 45%. Bioavailability may be slightly increased by food, or slightly decreased by antacids; however, these effects are of no clinical consequence. Famotidine undergoes minimal first-pass metabolism. After oral doses, peak plasma levels occur in 1 to 3 hours. Plasma levels after multiple doses are similar to those after single doses. Fifteen to 20% of famotidine in plasma is protein bound. Famotidine has an elimination half-life of 2.5 to 3.5 hours. Famotidine is eliminated by renal (65 to 70%) and metabolic (30 to 35%) routes. Renal clearance is 250 to 450 mL/min, indicating some tubular excretion. Twenty-five to 30% of an oral dose and 65 to 70% of an intravenous dose are recovered in the urine as unchanged compound. The only metabolite identified in man is the S-oxide.   
  
There is a close relationship between creatinine clearance values and the elimination half-life of famotidine. In patients with severe renal insufficiency, i.e., creatinine clearance less than 10 mL/min, the elimination half-life of famotidine may exceed 20 hours and adjustment of dose or dosing intervals in moderate and severe renal insufficiency may be necessary (see PRECAUTIONS, DOSAGE AND ADMINISTRATION).   
  
In elderly patients, there are no clinically significant age-related changes in the pharmacokinetics of famotidine. However, in elderly patients with decreased renal function, the clearance of the drug may be decreased (see PRECAUTIONS, Geriatric Use).